COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny’s sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.
Source: Reuters Medical News